A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the bleeding safety (the composite endpoint of major
and clinically relevant non-major bleeding) of 2 doses of apixaban (2.5 mg BID and 5.0 mg
BID) or placebo in combination with standard therapy (aspirin and /or additional antiplatelet
therapy) over a 24 week treatment period in selected subjects with recent (≤7 days) acute
coronary syndrome.